Xcout IntelOncXerna Therapeutics, Ltd. competitors & alternatives
The 12 closest competitors and alternatives to OncXerna Therapeutics, Ltd. among life sciences companies — ranked by similarity to what OncXerna Therapeutics, Ltd. actually does, not by market-cap band.
Subscribe to see OncXerna Therapeutics, Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About OncXerna Therapeutics, Ltd.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
OncXerna Therapeutics, Ltd. at a glance
OncXerna Therapeutics, Ltd. is a life sciences company headquartered in United States. Its most recent funding round raised $30M in February 2022.
OncXerna Therapeutics, Ltd. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $30M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 OncXerna Therapeutics, Ltd. competitors
Ranked by semantic similarity — how close each company is to OncXerna Therapeutics, Ltd. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Biotechnology
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Biotech
AUM Biosciences is a clinical-stage biotechnology company that develops precision oncology therapeutics utilizing multi-faceted inhibition strategies to overcome cancer drug resistance. The company serves patients and the healthcare sector by advancing a targeted clinical pipeline designed to combat tumor evasion and treatment resistance.
Biotechnology
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Biotech
Oncodesign Precision Medicine is a biopharmaceutical company that develops innovative therapeutic and diagnostic solutions targeting treatment resistance, metastasis, and diseases such as oncology, inflammatory bowel disease, and Parkinson's disease. Utilizing proprietary technologies like OncoSNIPER, Nanocyclix, and PROMETHE, the company advances first-in-class and best-in-class precision medicine programs to serve patients, clinicians, and pharmaceutical partners.
Biotech
Fore Biotherapeutics is a virtual precision oncology company rooted in science and innovation, with expertise and talent across the USA. The company is focused on developing treatments, including its Plixorafenib Program.
Biotechnology
OncoSenX, Inc. is a late-stage preclinical biotechnology company headquartered in Seattle, Washington. The firm specializes in developing targeted cancer therapeutics and novel drug delivery pipelines. Its oncology technology works in coordination with parent company Entos's research platforms to advance precision gene therapies.
Biotechnology
One Biosciences is a biotechnology company headquartered in Paris, France. It is driven by innovative scientists and biotech leaders focused on advancing precision medicine and novel therapies for patients.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Biotech
Rznomics is a South Korean biotechnology company developing RNA-based gene therapies using a trans-splicing ribozyme platform. Its programs are focused primarily on therapeutic applications in cancer and other serious diseases, serving patients through prospective drug-development and clinical partnerships.
Biotechnology
CatchMe Therapeutics is a biotechnology company headquartered in Ness Ziona, Israel, founded in August 2021. The firm develops RNA-based medicines and precision medicine solutions focusing on RNA-binding proteins for cancer-related therapies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of OncXerna Therapeutics, Ltd. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for OncXerna Therapeutics, Ltd.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →